5-Methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), widely known by its street name "Moxy," occupies a unique niche among psychedelic tryptamines. Where most classical psychedelics are defined by their visual effects, 5-MeO-MiPT is distinguished by its pronouncedtactile and body-focused effects -- heightened physical sensation, erotic enhancement, empathogenic warmth, and a stimulant-like energy that sets it apart from the more contemplative character of psilocybin or DMT .
The compound's synthesis was first reported by Repke, Davis, and Ferguson in 1985, but it was Alexander Shulgin who brought it to wider attention through his personal bioassays documented in TiHKAL (Tryptamines I Have Known and Loved, 1997). Shulgin reported that oral doses of 4-6 mg produced heightened sensory acuity -- particularly tactile and erotic -- alongside mild visual distortions and a persistent euphoria lasting 4-6 hours .
Pharmacologically, 5-MeO-MiPT is more complex than most tryptamine psychedelics. Beyond its agonist activity at 5-HT2A and 5-HT1A receptors (the standard psychedelic mechanism), it displays notable serotonin and norepinephrine reuptake inhibition (SNRI-like activity), which likely accounts for its stimulant qualities and the pronounced body effects that distinguish it from simpler tryptamines . This dual mechanism -- psychedelic plus monoamine reuptake inhibition -- makes 5-MeO-MiPT a pharmacological hybrid that demands particular caution regarding drug interactions.
References
Shulgin A, Shulgin A. TiHKAL: Tryptamines I Have Known and Loved. Transform Press. 1997. Entry #40. Repke DB, et al. Synthesis of N,N-dialkylated 5-methoxytryptamines. Journal of Heterocyclic Chemistry. 1985;22:1079-1083. Rickli A, et al. Pharmaco-toxicological effects of 5-MeO-MiPT on motor, sensorimotor, physiological, and cardiorespiratory parameters. Frontiers in Pharmacology. 2024;15:1335338.
Safety at a Glance
High Risk- Harm Reduction Guidelines for 5-MeO-MiPT
- Start Low, Go Slow -- This Is Not Optional
- Toxicity: Toxicity and Safety Profile Limited but Concerning Data Compared to simpler 4-substituted tryptamines, 5-MeO-MiPT car...
- Dangerous with: Harmala alkaloid, PCP, Peganum harmala, Cocaine
- Overdose risk: Fatal overdose from 5-MeO-MiPT alone, at doses within the typical recreational range, is extremel...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
smoked
Duration
oral
Total: 5 hrs – 8 hrssmoked
Total: 5 hrs – 8 hrsHow It Feels
The onset of 5-MeO-MiPT — commonly called Moxy — arrives as a gentle warming that spreads upward through the body within twenty to thirty minutes of ingestion. A buzzing, pleasurable energy builds in the chest and limbs, similar in character to the body high of MDMA but softer and more diffuse. Nausea is possible, typically mild, and passes within the first hour. The first mental changes are a brightening of mood and a growing sense of social ease — conversations that might normally feel effortful become fluid and enjoyable, and there is a quiet dissolution of the usual barriers between inner experience and outward expression.
As the experience develops, the tactile dimension takes center stage. Touch becomes remarkably enhanced: fabrics feel richer, skin contact becomes intensely pleasurable, and the body's sensitivity to temperature, pressure, and texture is heightened to a degree that is genuinely remarkable. Unlike the raw electric intensity of Foxy, Moxy's tactile enhancement is warm and gentle — an amplification of natural sensation rather than a distortion of it. Visually, the effects are modest: mild color enhancement, a gentle softening of edges, and occasional subtle patterning on surfaces. The visual dimension is secondary to the somatic and empathogenic effects.
At the peak, roughly sixty to ninety minutes in and lasting two to three hours, Moxy reveals its empathogenic character. There is a warmth toward others that feels authentic and unprompted — not the overwhelming, urgent love of MDMA but a quieter, steadier emotional openness. Conversations go deeper without strain, physical affection feels natural and welcome, and there is a sense of being genuinely present with other people. The body feels wonderful: warm, buzzing gently, and deeply comfortable. Music is enhanced, particularly in its emotional and tactile dimensions — bass frequencies seem to resonate in the body, and melodies carry an emotional clarity that can be deeply moving.
The comedown is gradual and comfortable, the warmth and tactile enhancement slowly fading over two to three hours. The total duration is typically four to six hours. There is a pleasant afterglow of emotional openness and physical contentment that can last into the following day. Sleep comes naturally, though the residual warmth and social energy may delay it slightly. The overall character of Moxy is that of a gentle, body-centered psychedelic with genuine empathogenic qualities — less visually dramatic than most tryptamines, but offering a warmth and physical pleasure that is distinctively its own.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(14)
- Abnormal heartbeat— Abnormal heartbeat (arrhythmia) is any deviation from the heart's normal rhythm — including beats th...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Diarrhea— Diarrhea is the occurrence of frequent, loose, or watery bowel movements as a side effect of certain...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Stomach bloating— Stomach bloating is the uncomfortable distension of the abdomen resulting from gas accumulation, flu...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(14)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(14)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Depersonalization— A detachment from one's own sense of self, body, or mental processes, as if observing oneself from o...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Empathy enhancement— A state of intensified compassion and emotional openness in which one feels deeply connected to othe...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Multi-sensory(1)
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Pharmacology
Pharmacology
5-MeO-MiPT's pharmacological profile is notably more complex than that of most classical tryptamine psychedelics, combining serotonin receptor agonism with significant monoamine transporter activity.
Serotonin Receptor Activity
In vitro functional assays demonstrate that 5-MeO-MiPT is a full agonist at the 5-HT2A receptor with an EC50 of approximately 0.023 uM, placing it among the more potent tryptamine psychedelics at this key receptor . However, like its parent compound 5-MeO-DMT, 5-MeO-MiPT displayshigher affinity for the 5-HT1A receptor (Ki = 0.058 uM) compared to 5-HT2A (Ki = 0.163 uM) . This dual 5-HT1A/5-HT2A agonism likely contributes to its distinct phenomenological character -- the 5-HT1A activity may account for the empathogenic and anxiolytic qualities often reported, while 5-HT2A agonism drives the psychedelic component.
Monoamine Transporter Activity
What truly distinguishes 5-MeO-MiPT from most tryptamine psychedelics is its significant activity at monoamine transporters. Studies have identified it as a moderately potent serotonin-norepinephrine reuptake inhibitor (SNRI), with meaningful binding affinity at both the serotonin transporter (SERT) and the norepinephrine transporter (NET) . This SNRI-like activity is unusual among tryptamines and is likely responsible for thestimulant qualities that users consistently report -- increased energy, heightened tactile awareness, cardiovascular stimulation, and a "buzzing" body sensation that persists throughout the experience.
This transporter activity also has critical safety implications: it means 5-MeO-MiPT carries a more complex interaction profile than simpler tryptamines. Combining it with other serotonergic or noradrenergic agents creates a compounded risk of serotonin syndrome or hypertensive crisis.
Dose-Response Relationship
Pharmacological studies in mice have shown that 5-MeO-MiPT's effects are steeply dose-dependent, with a pronounced escalation from mild sensory enhancement at low doses to significant motor impairment, sensorimotor disruption, and cardiorespiratory changes at higher doses . At high doses, 5-MeO-MiPT induced apoptotic cell death through caspase activity in liver and brain tissue in animal models, though the relevance of these findings to human use at typical doses is unclear .
Metabolism
5-MeO-MiPT is metabolized primarily by CYP2D6 and CYP3A4 enzymes. Seven phase I metabolites have been identified in vitro, with demethylated and hydroxylated derivatives being the most prominent. In forensic case samples, four metabolites were detectable in blood and seven in urine .
References
Zwartsen A, et al. Pharmaco-toxicological effects of 5-MeO-MiPT on motor, sensorimotor, physiological, and cardiorespiratory parameters in mice. Frontiers in Pharmacology. 2024;15:1335338. Luethi D, et al. New Psychoactive Substance 5-MeO-MiPT In vivo Acute Toxicity and Histotoxicological Study. International Journal of Molecular Sciences. 2020;21(22):8547. Luethi D, et al. New Psychoactive Substance 5-MeO-MiPT In vivo Acute Toxicity. International Journal of Molecular Sciences. 2020;21(22):8547. Grafinger KE, et al. Study of the in vitro and in vivo metabolism of the tryptamine 5-MeO-MiPT using human liver microsomes and real case samples. Drug Testing and Analysis. 2018;10(3):562-574.
Detection Methods
Detection Methods
Standard Drug Screening
5-MeO-MiPT is not detected by standard immunoassay drug panels (the typical "5-panel," "10-panel," or "12-panel" tests used in employment, probation, and emergency medicine settings). These panels screen for broad drug classes (amphetamines, opiates, cannabinoids, benzodiazepines, cocaine metabolites) and lack cross-reactivity with substituted tryptamines .
Specialized Analytical Methods
Detection of 5-MeO-MiPT requires targeted analytical techniques:
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for confirming 5-MeO-MiPT in biological matrices. Modern forensic protocols can simultaneously screen for 5-MeO-MiPT alongside over 180 new psychoactive substances in whole blood, with high sensitivity and specificity .
High-resolution mass spectrometry (LC-HR-MS/MS) has been used for metabolite elucidation, identifying seven phase I metabolites in vitro (including demethylated and hydroxylated derivatives) and confirming four metabolites in blood and seven in urine from real forensic cases .
Gas chromatography-mass spectrometry (GC-MS), enhanced by chemometric analysis, provides an alternative confirmation method, particularly useful for seized material analysis .
A novel electrochemical screening method using screen-printed graphite electrodes with differential pulse adsorptive stripping voltammetry (DPAdSV) has been developed as a rapid, portable, field-deployable option, achieving a detection limit of 0.015 umol/L .
Forensic Challenges
The structural similarity of 5-MeO-MiPT to other 5-methoxy-substituted tryptamines (5-MeO-DMT, 5-MeO-DiPT, 5-MeO-DET) complicates identification, particularly with lower-resolution methods. Confirmatory analysis by LC-MS/MS or GC-MS with reference standards is essential to distinguish between structurally related tryptamines .
References
Melo LMA, et al. Electrochemistry of the synthetic tryptamine 5-MeO-MiPT at glassy carbon and screen-printed electrodes: A rapid and simple screening method for application in forensic analysis. Sensors and Actuators B: Chemical. 2023;395:134523. Grafinger KE, et al. Study of the in vitro and in vivo metabolism of the tryptamine 5-MeO-MiPT using human liver microsomes and real case samples. Drug Testing and Analysis. 2018;10(3):562-574. CFSRE. 5-MeO-MiPT Monograph. NMS Labs. 2019.
Interactions
| Substance | Status | Note |
|---|---|---|
| Harmala alkaloid | Dangerous | Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA |
| PCP | Dangerous | — |
| Peganum harmala | Dangerous | Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA |
| Cocaine | Unsafe | — |
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 2C-T-x | Uncertain | — |
| 2C-x | Uncertain | — |
| Cannabis | Uncertain | — |
| DOx | Uncertain | — |
| MDMA | Uncertain | — |
History
The history of 5-MeO-MiPT is intertwined with the broader story of psychedelic research, which has oscillated between periods of intense scientific interest and strict prohibition.
Like many psychedelic compounds, 5-MeO-MiPT was either synthesized in a laboratory setting or identified as a naturally occurring psychoactive substance through ethnobotanical research. The mid-20th century saw an explosion of interest in psychedelic compounds, with researchers exploring their potential applications in psychotherapy, creativity enhancement, and the study of consciousness.
The political and cultural backlash of the late 1960s and early 1970s led to the criminalization of most psychedelic substances, effectively halting legitimate research for decades. The resurgence of psychedelic research beginning in the 2000s — often called the "psychedelic renaissance" — has renewed scientific interest in this class of compounds, with clinical trials exploring applications in treatment-resistant depression, PTSD, end-of-life anxiety, and addiction.
5-MeO-MiPT exists within this broader pharmacological and cultural context, with its specific history shaped by its date of discovery, legal status, availability, and unique pharmacological profile.
Harm Reduction
Harm Reduction Guidelines for 5-MeO-MiPT
Start Low, Go Slow -- This Is Not Optional
5-MeO-MiPT has a steep dose-response curve. The difference between a pleasant, tactile-enhancing experience and an overwhelming, physically uncomfortable one can be as little as 2-3 mg. Combined with significant batch-to-batch variability in research chemical purity, precise dosing is critical .
Oral dosing guidelines:
- Threshold: 2-3 mg
- Light: 3-5 mg
- Common: 5-8 mg
- Strong: 8-12 mg
- Heavy: 12+ mg (high risk of adverse effects)
Always use a milligram-precision scale (0.001g resolution). Eyeballing doses of 5-MeO-MiPT is genuinely dangerous given the steep dose-response. If you cannot weigh your dose accurately, do not take it.
Drug Interaction Warnings
Due to 5-MeO-MiPT's SNRI-like pharmacology, it carries more interaction risks than most tryptamines :
- MAOIs (including ayahuasca/harmalas): Absolutely contraindicated. Risk of severe serotonin syndrome and potentially fatal hypertensive crisis
- SSRIs/SNRIs: Dangerous combination. Increased risk of serotonin syndrome
- Stimulants (amphetamine, cocaine, methylphenidate): Risk of cardiovascular crisis. The stimulant qualities of 5-MeO-MiPT are already significant; stacking additional stimulants is reckless
- MDMA/MDA: Extremely risky due to overlapping serotonergic and noradrenergic mechanisms
- Tramadol: Seizure risk in addition to serotonin syndrome risk
- Lithium: Contraindicated with all psychedelics; seizure risk
Managing Body Load
5-MeO-MiPT commonly produces significant body load -- muscle tension, jaw clenching, nausea, gastrointestinal discomfort, and sometimes uncomfortable cardiovascular stimulation. To manage this :
- Stay hydrated but don't overhydrate
- Magnesium supplementation before dosing may help with muscle tension
- Ginger tea can help with nausea
- Have a comfortable environment where you can lie down if needed
- Light movement and stretching can help with restlessness
General Best Practices
- Test your substance with a reagent kit (Ehrlich and Marquis at minimum)
- Have a sober sitter, particularly at higher doses
- Do not combine with alcohol (adds cardiovascular strain and impairs judgment)
- Allow at least 2 weeks between uses for tolerance reset
- Avoid if you have cardiovascular conditions, hypertension, or seizure disorders
References
Shulgin A, Shulgin A. TiHKAL: Tryptamines I Have Known and Loved. Transform Press. 1997. Entry #40. Zwartsen A, et al. Pharmaco-toxicological effects of 5-MeO-MiPT. Frontiers in Pharmacology. 2024;15:1335338.
Toxicity & Safety
Toxicity and Safety Profile
Limited but Concerning Data
Compared to simpler 4-substituted tryptamines, 5-MeO-MiPT carries a somewhat higher risk profile due to its more complex pharmacology, particularly its SNRI-like monoamine transporter activity.
Animal Toxicology
Preclinical studies in mice demonstrated dose-dependent toxic effects. At low doses (1 mg/kg), 5-MeO-MiPT produced no serious histopathological effects on liver, kidney, or brain tissue. However, at high doses (10+ mg/kg), the compound induced apoptotic cell death through caspase activity in multiple organ systems . The substance also produced significant cardiorespiratory changes at higher doses, including altered heart rate and breathing patterns .
Human Case Reports
A human poisoning case reported in the pharmacological literature described significant physiological and neurological symptoms following 5-MeO-MiPT ingestion, prompting the preclinical investigation that confirmed dose-dependent toxicity . The specific symptoms included motor impairment, autonomic instability, and prolonged altered mental status.
Interaction Risk Profile
5-MeO-MiPT's SNRI-like activity creates a broader interaction danger profile than most tryptamine psychedelics. Substances that should be strictly avoided include:
- MAOIs (including ayahuasca, Syrian rue, pharmaceutical MAOIs)
- SSRIs and SNRIs (risk of serotonin syndrome)
- Stimulants (amphetamines, cocaine -- risk of hypertensive crisis and cardiovascular strain)
- Other serotonergic drugs (tramadol, dextromethorphan, MDMA)
The compound's monoamine reuptake inhibition means that even without exogenous MAOIs, 5-MeO-MiPT intrinsically elevates synaptic serotonin and norepinephrine levels, lowering the threshold for serotonergic toxicity .
References
Luethi D, et al. New Psychoactive Substance 5-MeO-MiPT In vivo Acute Toxicity and Histotoxicological Study. International Journal of Molecular Sciences. 2020;21(22):8547. Zwartsen A, et al. Pharmaco-toxicological effects of 5-MeO-MiPT on motor, sensorimotor, physiological, and cardiorespiratory parameters in mice. Frontiers in Pharmacology. 2024;15:1335338.
Addiction Potential
not habit-forming
Overdose Information
Fatal overdose from 5-MeO-MiPT alone, at doses within the typical recreational range, is extremely unlikely based on the available evidence for classical psychedelics. The therapeutic index for most psychedelics is very wide.
However, psychological emergencies can occur and require appropriate response:
- Severe anxiety, panic, or psychotic episodes
- Dangerous behavior due to impaired reality testing
- Self-harm in the context of a distressing experience
Emergency management: If someone is experiencing a severe adverse reaction, move them to a calm, quiet environment. Speak reassuringly. Do not restrain unless there is immediate danger. Benzodiazepines (if available and the person is conscious and able to swallow) can reduce acute anxiety. If psychotic symptoms, self-harm risk, or medical distress is present, seek emergency medical attention.
Medical attention: Seek help immediately for seizures, extremely elevated body temperature, signs of serotonin syndrome (agitation, tremor, diarrhea, rapid heart rate), or if the substance consumed is uncertain.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA
Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA
Tolerance
| Full | almost immediately after ingestion |
| Half | 3 days |
| Zero | 7 days |
Cross-tolerances
Legal Status
Legal Status
United States
The legal status of 5-MeO-MiPT in the United States has been subject to regulatory proceedings. The DEA proposed placing 5-MeO-MiPT into Schedule I of the Controlled Substances Act as part of a broader action covering five tryptamines (alongside 4-OH-DiPT, 5-MeO-AMT, 5-MeO-DET, and DiPT). However, following expert testimony challenging the scientific basis of the scheduling, the DEAwithdrew the proposed rule . As of current reporting, 5-MeO-MiPT is not federally scheduled by specific name but may be prosecuted under theFederal Analogue Act as a substantially similar compound to scheduled tryptamines.
At the state level, 5-MeO-MiPT is explicitly Schedule I in Florida andSchedule I in Louisiana (since June 2013). Minnesota has also banned it as part of broader new psychoactive substance legislation .
International Status
- United Kingdom: Controlled as a Class A substance under the Misuse of Drugs Act 1971 (as a tryptamine derivative)
- Japan: Controlled as a "Designated Substance" (Shitei-Yakubutsu) under the Pharmaceutical Affairs Law, making possession and sale illegal
- Finland: Banned since December 2014
- Germany: Controlled under the Neue-psychoaktive-Stoffe-Gesetz (NpSG) blanket ban on new psychoactive substances
- Sweden: Classified as a controlled substance
- Australia: Controlled as an analogue under federal scheduling
The HHS has stated that 5-MeO-MiPT is not FDA-approved for any therapeutic use .
References
Federal Register. Schedules of Controlled Substances: Placement of 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT in Schedule I. 2022. Psychedelic Alpha. Inside the Challenge to DEA's Proposed Scheduling of 5 Psychedelic Tryptamines. Erowid. 5-MeO-MIPT Legal Status.
Experience Reports (1)
Tips (8)
5-MeO-MiPT is widely regarded as one of the best substances for tactile and sensory enhancement. At moderate doses (6-10mg) it provides strong body euphoria and entactogenic warmth without heavy visual distortion.
Start low with 5-MeO-MiPT, around 4-6mg orally. The dose-response curve is steep and going from 8mg to 12mg can be the difference between a pleasant entactogenic experience and an overwhelming trip.
Be very careful combining 5-MeO-MiPT with MDMA or other serotonergic substances. As a tryptamine with some serotonin releasing activity, the combination could increase risk of serotonin syndrome.
Set and setting are paramount with 5-MeO-MiPT. Choose a familiar, comfortable environment where you feel safe. Have trusted company or a trip sitter, especially for your first experience. Avoid stressful locations or social obligations.
Gastrointestinal discomfort is common with oral dosing of 5-MeO-MiPT. Taking it on a light stomach and having ginger tea available can help. Some users report that sublingual administration reduces nausea.
The freebase form of 5-MeO-MiPT is still active orally but may have slightly different onset timing. HCl salt is generally preferred for more predictable dosing and easier measurement on a milligram scale.
Community Discussions (3)
See Also
References (6)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- MDMA-assisted therapy for PTSD — Mithoefer et al. Psychopharmacology (2019)paper
- PubChem: 5-MeO-MiPT
PubChem compound page for 5-MeO-MiPT (CID: 2763156)
pubchem - 5-MeO-MiPT - TripSit Factsheet
TripSit factsheet for 5-MeO-MiPT
tripsit - 5-MeO-MiPT - Wikipedia
Wikipedia article on 5-MeO-MiPT
wikipedia